Compare Amphastar Pharmaceuticals Inc (AMPH) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Krispy Kreme Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.45 (market cap $863.95M), while Krispy Kreme Inc trades at $3.12 (market cap $544.79M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Krispy Kreme Inc pays a 3.47% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DNUT | |
|---|---|---|
Market Cap | $863.95M | $544.79M |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $4.70 |
52-Week Low | $16.87 | $2.92 |
Enterprise Value | $1.26B | $1.79B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Krispy Kreme (DNUT) trades at $3.34, up 3.41% today, with a bullish technical signal from oscillators and mixed earnings history. The company reported a net loss of -$515.77M in 2025 but shows margin improvement and a capital-light refranchising strategy. Recent news highlights a turnaround focus, with the CEO affirming progress on profitability and leverage reduction.
Outlook hinges on execution of the turnaround plan; opportunities include international expansion and cost controls, but risks persist from high debt and competitive pressures. Analysts are cautiously optimistic with a 50% buy rating, though negative profitability metrics warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
